Significance of fibrinogen, D-dimer, and LDH levels in predicting the risk of bleeding in patients with acute promyelocytic leukemia

Leukemia Research

Volumn 35, Issue 2, 2011, Pages 152-158

  Kim, Dae Young ^a   Lee, Je Hwan ^a   Lee, Jung Hee ^a   Kim, Sung Doo ^a   Lim, Sung Nam ^a   Choi, Yunsuk ^a   Lee, Young Shin ^a   Kang, Young Ah ^a   Seol, Miee ^a   Jeon, Mijin ^a   Kim, Joo Youn ^a   Lee, Kyung Hwa ^a   Lee, Yeon Joo ^a   Lee, Kyoo Hyung ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Acute promyelocytic leukemia; ATRA; Bleeding; D dimer; Fibrinogen; LDH

Indexed keywords

ANTHRACYCLINE; CYTARABINE; D DIMER; DAUNORUBICIN; FIBRINOGEN; IDARUBICIN; LACTATE DEHYDROGENASE; RETINOIC ACID;

ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLEEDING DISORDER; BLOOD TRANSFUSION; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE FREE SURVIVAL; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG RESPONSE; ENZYME BLOOD LEVEL; FEMALE; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATIENT MONITORING; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN FUNCTION; RESPIRATORY TRACT HEMORRHAGE; RISK ASSESSMENT; SURVIVAL TIME; THROMBIN TIME; THROMBOCYTE COUNT; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; HEMORRHAGE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; L-LACTATE DEHYDROGENASE; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TRETINOIN; YOUNG ADULT;

EID: 78751702921     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.05.022     Document Type: Article

References (26)

1. Wang Z.Y., Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008, 111:2505-2515.
2. Tallmann M.S. Curative therapeutic approaches to APL. Ann Hematol 2004, 83(Suppl. 1):S81-S82.
3. Avvisati G., Petti M.C., Lo-Coco F., Vegna M.L., Amadori S., Baccarani M., et al. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Blood 2002, 100:3141-3146.
4. Marty M., Ganem G., Fischer J., Flandrin G., Berger R., Schaison G., et al. Acute promyelocytic leukemia: retrospective study of 119 patients treated with daunorubicin. Nouv Rev Fr Hematol 1984, 26:371-378.
5. Stein E., McMahon B., Kwaan H., Altman J.K., Frankfurt O., Tallman M.S. The coagulopathy of acute promyelocytic leukaemia revisited. Best Pract Res Clin Haematol 2009, 22:153-163.
6. Lee K.H., Kim D.H., Lee J.S., Suh C.W., Kim S.W., Kim S.B., et al. Acute promyelocytic leukemia is a distinct subset of acute myelocytic leukemia with unique clinicopathologic characteristics including longer duration of relapse free survival: experience in 13 cases. J Kor Med Sci 1994, 9:437-443.
7. Hoyle C.F., Swirsky D.M., Freedman L., Hayhoe F.G. Beneficial effect of heparin in the management of patients with APL. Br J Haematol 1988, 68:283-289.
8. Kingsley E.C., Durie B.G., Garewal H.S. Acute promyelocytic leukemia. West J Med 1987, 146:322-327.
9. Cordonnier C., Vernant J.P., Brun B., Heilmann M.G., Kuentz M., Bierling P., et al. Acute promyelocytic leukemia in 57 previously untreated patients. Cancer 1985, 55:18-25.
10. Kim H., Lee J.H., Choi S.J., Lee J.H., Seol M., Lee Y.S., et al. Risk score model for fatal intracranial hemorrhage in acute leukemia. Leukemia 2006, 20:770-776.
11. Sanz M.A., Grimwade D., Tallman M.S., Lowenberg B., Fenaux P., Estey E.H., et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009, 113:1875-1891.
12. Tallman M.S., Altman J.K. How I treat acute promyelocytic leukemia. Blood 2009, 114:5126-5135.
13. Wilde J.T., Davies J.M. Haemostatic problems in acute leukaemia. Blood Rev 1990, 4:245-251.
14. Dombret H., Sutton L., Duarte M., Daniel M.T., Leblond V., Castaigne S., et al. Combined therapy with all-trans-retinoic acid and high-dose chemotherapy in patients with hyperleukocytic acute promyelocytic leukemia and severe visceral hemorrhage. Leukemia 1992, 6:1237-1242.
15. Fenaux P., Chastang C., Chevret S., Sanz M., Dombret H., Archimbaud E., et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999, 94:1192-1200.
16. Burnett A.K., Grimwade D., Solomon E., Wheatley K., Goldstone A.H. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood 1999, 93:4131-4143.
17. de la Serna J., Montesinos P., Vellenga E., Rayon C., Parody R., Leon A., et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 2008, 111:3395-3402.
18. Di Bona E., Avvisati G., Castaman G., Luce Vegna M., De Sanctis V., Rodeghiero F., et al. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia. Br J Haematol 2000, 108:689-695.
19. NCI Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events, Version 3.0 2003, National Institutes of Health, [10/22/2003 cited; Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcae_index.pdf].
20. Yanada M., Matsushita T., Asou N., Kishimoto Y., Tsuzuki M., Maeda Y., et al. Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. Eur J Haematol 2007, 78:213-219.
21. Jacomo R.H., Melo R.A., Souto F.R., de Mattos E.R., de Oliveira C.T., Fagundes E.M., et al. Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica 2007, 92:1431-1432.
22. Kim J., Hajjar K.A. Annexin II: a plasminogen-plasminogen activator co-receptor. Front Biosci 2002, 7:d341-d348.
23. Tallman M.S., Hakimian D., Kwaan H.C., Rickles F.R. New insights into the pathogenesis of coagulation dysfunction in acute promyelocytic leukemia. Leuk Lymphoma 1993, 11:27-36.
24. Dombret H., Scrobohaci M.L., Ghorra P., Zini J.M., Daniel M.T., Castaigne S., et al. Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-trans retinoic acid treatment. Leukemia 1993, 7:2-9.
25. Meijers J.C., Oudijk E.J., Mosnier L.O., Bos R., Bouma B.N., Nieuwenhuis H.K., et al. Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia. Br J Haematol 2000, 108:518-523.
26. Schoch C., Haase D., Haferlach T., Freund M., Link H., Lengfelder E., et al. Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17)(q22;q21): a report on 50 patients. Br J Haematol 1996, 94:493-500.